Related Experiment Video
Updated: Mar 21, 2026
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy
Laurène Leclair-Visonneau1, Tiphaine Rouaud2, Bérangère Debilly3
1Inserm, CIC-04, Nantes F-44093, France; CHU Nantes, Department of Neurology, Nantes F-44093, France; CHU Nantes, Department of Physiology, Nantes F-44093, France.
Objectives:
Results from preclinical studies suggest that inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for tauopathies. The aim of the present study was therefore to determine the effects of sodium valproate (VPA), a GSK-3 inhibitor, on disease progression in progressive supranuclear palsy (PSP).
Patients And Methods:
We performed a double-blind, randomized, placebo-controlled trial, in 28 PSP patients who received VPA (1500mg/day) or matching placebo for 24 months. The primary endpoint was the change from baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at 12 and 24 months. Secondary endpoints evaluated the effects of VPA on cognitive and behavioral status (MMSE, Mattis Dementia Rating Scale, Wisconsin Card Sorting, Gröber and Buschke and Oral Denomination 80 tests), tolerability of treatment, and patient compliance.
Results:
There were no baseline differences between active treatment and placebo groups in age and clinical rating scores. PSPRS score at 12 months was significantly higher in the VPA than in the placebo group (60.8±20 versus 46.9±18.6 respectively, p=0.01), but was similar between the two groups at 24 months. No significant differences were observed between VPA and placebo groups for the secondary endpoints.
Conclusion:
Our results suggest that VPA is not effective as a disease-modifying agent in PSP.
